| Literature DB >> 24782508 |
Yirui Chen1, Shouyun Li1, Chunlin Zhou2, Chengwen Li3, Kun Ru3, Qing Rao1, Haiyan Xing1, Zheng Tian1, Kejing Tang1, Yingchang Mi2, Baohong Wang4, Min Wang1, Jianxiang Wang5.
Abstract
The majority of acute promyelocytic leukemia (APL) cases are characterized by the PML-RARα fusion gene. Although the PML-RARα fusion gene can be detected in >98% of APL cases, RARα is also found to be fused with other partner genes, which are also related to all-trans retinoic acid (ATRA)-dependent transcriptional activity and cell differentiation. In this study, we identified a novel RARα fusion gene, TBLR1-RARα (GenBank KF589333), in a rare case of APL with a t(3;17)(q26;q21),t(7;17)(q11.2;q21) complex chromosomal rearrangement. To our knowledge, TBLR1-RARα is the 10th RARα chimeric gene that has been reported up to now. TBLR1-RARα contained the B-F domains of RARα and exhibited a distinct subcellular localization. It could form homodimers and also heterodimers with retinoid X receptor α. As a result, TBLR1-RARα exhibited diminished transcriptional activity by recruitment of more transcriptional corepressors compared with RARα. In the presence of pharmacologic doses of ATRA, TBLR1-RARα could be degraded, and its homodimerization was abrogated. Moreover, when treated with ATRA, TBLR1-RARα could mediate the dissociation and degradation of transcriptional corepressors, consequent transactivation of RARα target genes, and cell differentiation induction in a dose- and time-dependent manner.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24782508 DOI: 10.1182/blood-2013-10-528596
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113